Structure Therapeutics (GPCR) just moved its obesity pipeline up a gear by kicking off a first in human Phase 1 trial for ACCG-2671, its oral amylin receptor agonist targeting metabolic disease. See ...
A conserved signaling axis linking Drosophila adipose tissue to nephrocyte function reveals how obesity can drive kidney dysfunction and points to new opportunities for therapeutic intervention.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback